Title :

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by <i>KRAS</i> Mutation Subtypes.

Author(s) :

Ruppert, A. M. [Auteur]
Groupe de recherche clinique Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules [GRC 4 - Theranoscan]
Assistance publique - Hôpitaux de Paris (AP-HP) [AP-HP]
CHU Tenon [AP-HP]
Beau-Faller, M. [Auteur]
Interface de Recherche Fondamentale et Appliquée en Cancérologie [IRFAC - Inserm U1113]
Hôpital de Hautepierre [Strasbourg]
Debieuvre, Didier [Auteur]
Centre Hospitalier Emile Muller [Mulhouse] [CH E.Muller Mulhouse]
Ouafik, L. [Auteur]
Hôpital Nord [CHU - APHM]
Institut de neurophysiopathologie [INP]
Westeel, V. [Auteur]
Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) [RIGHT]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Rouquette, I. [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Mazières, Julien [Auteur]
Université Toulouse III - Paul Sabatier [UT3]
Service Pneumologie-Allergologie [CHU Toulouse]
Bringuier, P. P. [Auteur]
Hospices Civils de Lyon [HCL]
Université Claude Bernard Lyon 1 [UCBL]
Monnet, Isabelle [Auteur]
Service de Pneumologie [CHI Créteil]
Narducci, Fabienne [Auteur]
Maladies Rares du Développement : Génétique, Régulation et Protéomique (RADEME) - ULR 7364
Ricordel, C. [Auteur]
Service de pneumologie [Rennes] = Pneumology [Rennes]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
Chemistry, Oncogenesis, Stress and Signaling [COSS]
Merlio, J. P. [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU de Bordeaux]
Bordeaux Research In Translational Oncology [Bordeaux] [BaRITOn]
Janicot, H. [Auteur]
CHU Gabriel Montpied [Clermont-Ferrand]
Lemoine, A. [Auteur]
Hôpital Paul Brousse
Assistance publique - Hôpitaux de Paris (AP-HP) [AP-HP]
Physiopathogénèse et Traitement des Maladies du Foie
Foucher, P. [Auteur]
Férération d'oncologie thoracique (CHU de Dijon)
Poudenx, M. [Auteur]
Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] [UNICANCER/CAL]
Morin, F. [Auteur]
Intergroupe Francophone de Cancérologie Thoracique [Paris] [IFCT]
Langlais, A. [Auteur]
Intergroupe Francophone de Cancérologie Thoracique [Paris] [IFCT]
Souquet, P. J. [Auteur]
Service de pneumologie [Centre Hospitalier Lyon Sud - HCL]
Hospices Civils de Lyon [HCL]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Barlesi, F. [Auteur]
Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM]
Aix Marseille Université [AMU]
Assistance Publique - Hôpitaux de Marseille [APHM]
Wislez, M. [Auteur]
Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)]
Hôpital Cochin [AP-HP]

Journal title :

Jto Clinical and Research Reports

Abbreviated title :

JTO Clin Res Rep

Volume number :

1

Pages :

100052

Publication date :

2021-10-10

ISSN :

2666-3643

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Introduction KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Methods In the Biomarkers France study, 4894 KRAS ...
Show more >Introduction KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Methods In the Biomarkers France study, 4894 KRAS mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the KRAS mutations subtype. Results Over 95% of patients with KRAS mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma (82.5%). The most common KRAS mutation subtype was G12C (374 patients; 41.5%), followed by G12V (168; 18.6%), G12D (131; 14.5%), G12A (62; 6.9%), G13C (45; 5.0%), G13D (31; 3.4%), and others (10; 1%). Approximately 21% of patients had transition mutation and 68.2% had a transversion mutation. G12D and transition mutations were predominant in never-smokers. The median overall survival for patients with KRAS-mutated NSCLC was 8.1 months (95% confidence interval [CI]: 7.5–9.5), without any differences according to the different KRAS subtypes mutations. The median progression-free survival was 4.6 months (95% CI: 4.2–5.1) for first-line treatment and 4.8 months (95% CI: 4.3–6.8) for second-line treatment, without any differences according to the different KRAS subtypes mutations. Conclusions KRAS mutation subtypes influenced neither treatment responses nor outcomes. The KRAS G12C mutation was detected in 41.5% of patients, who are now eligible for potent and specific G12C inhibitors.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Maladies Rares du Développement : Génétique, Régulation et Protéomique (RADEME) - ULR 7364

Submission date :

2023-06-05T07:12:32Z
2024-02-21T10:27:54Z